Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Robert, Caroline, Prof, Ribas, Antoni, Prof, Schachter, Jacob, Prof, Arance, Ana, MD, Grob, Jean-Jacques, Prof, Mortier, Laurent, Prof, Daud, Adil, Prof, Carlino, Matteo S, MB, McNeil, Catriona M, MD, Lotem, Michal, Prof, Larkin, James M G, Prof, Lorigan, Paul, Prof, Neyns, Bart, Prof, Blank, Christian U, Prof, Petrella, Teresa M, MD, Hamid, Omid, MD, Su, Shu-Chih, PhD, Krepler, Clemens, MD, Ibrahim, Nageatte, MD, Long, Georgina V, Prof
Published in The lancet oncology (01.09.2019)
Published in The lancet oncology (01.09.2019)
Get full text
Journal Article
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Long, Georgina V, Dr, Trefzer, Uwe, MD, Davies, Michael A, MD, Kefford, Richard F, Prof, Ascierto, Paolo A, MD, Chapman, Paul B, MD, Puzanov, Igor, MD, Hauschild, Axel, MD, Robert, Caroline, PhD, Algazi, Alain, MD, Mortier, Laurent, Prof, Tawbi, Hussein, PhD, Wilhelm, Tabea, MD, Zimmer, Lisa, MD, Switzky, Julie, MSN, Swann, Suzanne, PhD, Martin, Anne-Marie, PhD, Guckert, Mary, MSN, Goodman, Vicki, MD, Streit, Michael, MD, Kirkwood, John M, Prof, Schadendorf, Dirk, Prof
Published in The lancet oncology (01.11.2012)
Published in The lancet oncology (01.11.2012)
Get full text
Journal Article
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial
Basset-Seguin, Nicole, Prof, Hauschild, Axel, Prof, Grob, Jean-Jacques, Prof, Kunstfeld, Rainer, Prof, Dréno, Brigitte, Prof, Mortier, Laurent, Prof, Ascierto, Paolo A, Prof, Licitra, Lisa, MD, Dutriaux, Caroline, MD, Thomas, Luc, Prof, Jouary, Thomas, MD, Meyer, Nicolas, MD, Guillot, Bernard, Prof, Dummer, Reinhard, Prof, Fife, Kate, MD, Ernst, D Scott, Prof, Williams, Sarah, MSc, Fittipaldo, Alberto, MD, Xynos, Ioannis, MD, Hansson, Johan, Prof
Published in The lancet oncology (01.06.2015)
Published in The lancet oncology (01.06.2015)
Get full text
Journal Article
Dabrafenib plus trametinib in patients with BRAF V600–mutant melanoma brain metastases (COMBI-MB): a multi-cohort, open-label, phase 2 trial
Davies, Michael A, Saiag, Philippe, Robert, Caroline, Grob, Jean-Jacques, Flaherty, Keith T, Arance, Ana, Chiarion-Sileni, Vanna, Thomas, Luc, Lesimple, Thierry, Mortier, Prof Laurent, Moschos, Stergios J, Hogg, David, Márquez-Rodas, Iván, Del Vecchio, Michele, Lebbé, Céleste, Meyer, Nicolas, Zhang, Ying, Huang, Yingjie, Mookerjee, Bijoyesh, Long, Georgina V
Published in The lancet oncology (04.06.2017)
Published in The lancet oncology (04.06.2017)
Get full text
Journal Article
Dabrafenib plus trametinib in patients with BRAFV600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Davies, Michael A, Dr, Saiag, Philippe, Prof, Robert, Caroline, Prof, Grob, Jean-Jacques, Prof, Flaherty, Keith T, Prof, Arance, Ana, MD, Chiarion-Sileni, Vanna, MD, Thomas, Luc, Prof, Lesimple, Thierry, MD, Mortier, Laurent, Prof, Moschos, Stergios J, MD, Hogg, David, MD, Márquez-Rodas, Iván, Prof, Del Vecchio, Michele, Prof, Lebbé, Céleste, Prof, Meyer, Nicolas, Prof, Zhang, Ying, PhD, Huang, Yingjie, MD, Mookerjee, Bijoyesh, MD, Long, Georgina V, Prof
Published in The lancet oncology (01.07.2017)
Published in The lancet oncology (01.07.2017)
Get full text
Journal Article